deltatrials
Completed PHASE1 INTERVENTIONAL NCT00091585

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies

Sponsor: Sunesis Pharmaceuticals

Conditions Neoplasms
Interventions SNS-595
Updated 5 times since 2017 Last updated: May 9, 2007 Started: Jun 30, 2004 Completion: Nov 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neoplasms, this trial is completed. The trial is conducted by Sunesis Pharmaceuticals and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sunesis Pharmaceuticals
Data source: Sunesis Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations